My research interest has been in defining the molecular aspects of pathogenesis to impact the diagnosis, treatment, and rational development of therapeutics viral-induced diseases. Based upon his HIV research, I was Senior Therapeutic Area Advisor for Antivirals at GlaxoSmithKline (GSK)). Later, I became the Director of Technology Development in Translational Medicine and Genetics. A member of GSK’s Human Biomarker laboratory, I developed biomarker panels to develop new therapeutics. I am an advocate of the belief that disease understanding and technological advancements can impact the disconnect between discovery and the product development process. I was a founder and Chief Scientific Officer of Ridge diagnostics where I developed a biomarker-based test for major depressive disorder. I was also a co-founder of Innovalyst a life science consulting company supporting innovative research and development.
B.S. Biology, City College of New York, New York, NY
M.A. Microbiology, Southern Illinois University, Carbondale, IL
Ph.D. Molecular Biology, Albert Einstein College of Medicine, NY
Principal, Innovalyst ICAN LLC Parkville, MD: 2018-Present
Scientific Officer, Atlantic Diagnostics Laboratories, Bensalem PA: 2017-2018
President and CSO, Ridge Diagnostics, Durham NC: 2006-2016
Director, Technology Development, Translational Med.&Tech. GlaxoSmithKline, RTP NC: 2002-2005
Senior Therapeutic Area Advisor, Clinical Phamacol. Experimental Med. GSK, RTP NC: 2002
Director Preclinical R&D, VIRCO Lab USA, Rockville, MD: 2001
Director Preclinical R&D, SRA Life Sciences, Rockville, MD: 1998-2000
Visiting Scientist, SRA Life Sciences, Rockville, MD: 1996-1998
Director HIV Laboratories, Dept of Medicine, Division of Clinical Pharmacology, Albany Medical College, Albany NY: 1993-1998
Associate Professor, Dept of Medicine and Dept of Pharmacology Albany Medical College: 1992-1998
Associate Professor, Dept. of Medicine, Microbiology and Program in Oncology, University of Maryland School of Medicine, Baltimore, MD: 1989-1992
Chief, Molecular Biology Laboratory, VA Medical Center, Baltimore, MD
Assistant Professor, Microbiology and Oncology, of Maryland School of Medicine: 1985-1989
Instructor in Oncology, The Johns Hopkins University, School of Medicine, Baltimore, MD: 1981-1983
Wissen schaftlicher Assistant, Dept of Molecular Biology, Institute for Physiological Chemistry University of Hamburg. Hamburg, Germany: 1977-1981
NY State Scholarship; Special Doctoral Fellowship SIU; NIH Research Fellowship, Albert Einstein Coll. Med.;
Volkswagen Fellowship, University of Hamburg; Bressler Foundation Research Awards (3 separate Awards) University of Maryland.
Editor Antimicrobial Agents and Chemotherapy (1995-2012)
Member, IMST-12 SBIR, Devices and Detection Systems Review Panel, NIH, 2009
Member, NIH Challenge Grants Review Panel, NIMH, NIH 2009
Member, HIV/AIDS Clinical Trial Network Review Panel, NIAID, NIH, 2006
Member, HIV/AIDS Prevention Trials Network Review Panel, NIAID, NIH. 2005
Member, SBIR/STTR SSS-2 Study Section on Proteomic Technologies, CSR, NIH 2003-2004
US 8,158,374 – Materials and Methods related to diagnosing a clinical condition in a subject, or determining the subject’s predisposition to develop the clinical condition, using a multi-parameter system to measure a plurality of parameters and an algorithm to determine a disease score.
US 8,450,077 – Materials and methods related to materials and methods for diagnosing or assessing a clinical condition in a subject, or determining a subject’s predisposition to develop a clinical condition, using algorithms to determine a disease score based upon a combination of parameters.
US 8,440,418 – Materials and methods for using combinations of metabolic syndrome and HPA axis biomarkers for monitoring major depressive disorder.
JAPAN 5663314– Materials and Methods for Diagnosing and Monitoring Major Depressive Disorder assessing a clinical condition in a subject,
JAPAN 5658571- Inflammatory Biomarkers for Monitoring Depression Disorders assessing a clinical condition in a patient with a depression disorder.
JAPAN 5540000-Human Biomarker Hypermapping for Depressive Disorders. Materials and Methods for Hypermapping patient data in 3-Dimensional Space.
JAPAN 5767973- Metabolic Syndrome and HPA Axis Biomarkers for Monitoring Major Depressive Disorders. Using multiple biomarkers (MSX and HPA) to monitor the response of patients to treatment of Major Depressive Disorder.
JAPAN 5744063– Multiple Biomarker Panels to Stratify Disease Severity and Monitor Treatment of Depression
WIPO 2337866 -Human Biomarker Hypermapping for Depressive Disorders. Materials and Methods for Hypermapping patient data in 3-Dimensional Space.